Brain-Computer Interface Investment Landscape

Migration, Crosslink

📗 Cite This Artifact

←

Home / Artifacts / Brain-Computer Interface Investment Landscape

📖

Brain-Computer Interface Investment Landscape

active

wiki page Created: 2026-04-02T07:19:35 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-investment-brain-computer-interface

📖 Wiki Page

investment1018 wordssynced 2026-04-02

Executive Summary

Brain-Computer Interfaces (BCIs) represent a rapidly growing investment sector in neurotechnology, with particular relevance for neurodegenerative diseases. The technology enables direct communication between the brain and external devices, offering transformative applications for patients with ALS, locked-in syndrome, and other conditions causing severe motor impairment. This investment landscape analyzes the current BCI technology ecosystem, key players, funding trends, clinical applications, and strategic opportunities for investors and researchers in the neurodegeneration space. [@neuralink2024]

Technology Overview

BCI Modalities

Key Technology Categories

Invasive BCIs

Microelectrode arrays
Electrocorticography (ECO/CoG)
Highest signal quality
Surgical risk

Non-Invasive BCIs

Electroencephalography (EEG)
Magnetoencephalography (MEG)
Functional near-infrared spectroscopy (fNIRS)
Lower risk, lower signal resolution

Partially Invasive

Endovascular approaches
Subdural arrays
Balanced risk/benefit

Pipeline and Companies

Clinical-Stage BCI Companies

...

Executive Summary

Technology Overview

BCI Modalities

Key Technology Categories

Invasive BCIs

Microelectrode arrays
Electrocorticography (ECO/CoG)
Highest signal quality
Surgical risk

Non-Invasive BCIs

Electroencephalography (EEG)
Magnetoencephalography (MEG)
Functional near-infrared spectroscopy (fNIRS)
Lower risk, lower signal resolution

Partially Invasive

Endovascular approaches
Subdural arrays
Balanced risk/benefit

Pipeline and Companies

Clinical-Stage BCI Companies

| Company | Technology | Modality | Indication | Stage | Funding | [@synchron2024]
|---------|------------|----------|-------------|-------|---------| [@bci2023]
| Synchron | Stentrode | Endovascular | ALS, Stroke | Phase 1 | $70M+ | [@blackrock2023]
| Neuralink | N1 | Invasive | Paralysis | First-in-human | $280M+ | [@bci2024]
| Blackrock Neurotech | Utah Array | Invasive | Neural recording | Clinical | $50M+ |
| Paradromics | Connexus | Invasive | Communication | Preclinical | $35M+ |
| Motus | Myo | Non-invasive | Stroke rehab | Commercial | $20M+ |

Key Players

1. Neuralink (Elon Musk)

Technology: N1 implantable chip with 1,024 electrodes
Focus: Treat paralysis, restore movement
Funding: $280M (Series C, 2023)
Milestone: First human implantation (2024)
Valuation: ~$1B+

2. Synchron

Technology: Stentrode (endovascular BCI)
Focus: ALS, stroke communication
Funding: $70M+
Advantage: No brain surgery required
Status: Phase 1 trials

3. Blackrock Neurotech

Technology: Utah Array, Neuralink BCI
Focus: Long-term neural interfaces
Funding: $50M+
Products: CerePort, MoveAgain

4. Paradromics

Technology: Connexus direct data interface
Focus: Communication for paralysis
Funding: $35M+
Status: Preparing for clinical trials

Non-Invasive BCI Companies

| Company | Product | Technology | Application | Status |
|---------|---------|------------|-------------|--------|
| Emotiv | EPOC X | EEG | Research, Wellness | Commercial |
| OpenBCI | Galea | EEG+VR | Research | Commercial |
| NextMind | Dev Kit | EEG | Consumer | Commercial |
| Thought Technologies | Aura | EEG | Healthcare | Commercial |

Investment Analysis

Funding Trends (2020-2025)

| Year | Total Investment | Deal Count | Notable Deals |
|------|------------------|------------|---------------|
| 2020 | $180M | 12 | Synchron Series B |
| 2021 | $320M | 18 | Neuralink Series C |
| 2022 | $450M | 22 | Paradromics Series A |
| 2023 | $580M | 28 | Neuralink $280M |
| 2024 | $420M | 25 | Multiple Series rounds |
| 2025 | $250M | 15 | Early-stage focus |

Investment Themes

Invasive vs. Non-Invasive Balance

Invasive: Higher risk, higher reward
Non-invasive: Lower barrier to entry
Hybrid approaches gaining interest

Clinical Applications Focus

ALS communication
Stroke rehabilitation
Epilepsy monitoring
Movement disorders

Technology Advances

Higher channel counts
Better biocompatibility
Wireless connectivity
AI signal processing

Clinical Applications in Neurodegeneration

Current Applications

Amyotrophic Lateral Sclerosis (ALS)

Communication devices
Environmental control
Eye-tracking integration

Locked-In Syndrome

Communication restoration
Motor intention decoding

Stroke Rehabilitation

Motor imagery training
Neuroplasticity enhancement

Parkinson's Disease

Closed-loop deep brain stimulation
Movement prediction

Alzheimer's Disease

Memory augmentation (research)
Cognitive monitoring

Clinical Trials

Synchron COMMAND Trial

Status: Enrolling
Focus: Severe paralysis
Endpoints: Safety, communication

Neuralink PRECISION Trial

Status: First human
Focus: Quadriplegia
Endpoints: Cursor control, typing

Gap Analysis

Technical Gaps

Long-term Stability

Implant durability (10+ years needed)
Biocompatibility improvements
Encapsulation strategies

Signal Resolution

More channels needed
Better spike sorting
Lower noise

Wireless Systems

Need for fully implantable wireless
Power delivery
Data transmission

AI Integration

Better decoding algorithms
Real-time processing
Adaptive systems

Clinical Gaps

Patient Selection

Criteria for BCI implantation
Outcome prediction
Rehabilitation protocols

Regulatory Pathways

FDA approval processes
Reimbursement codes
Clinical trial design

Commercial Gaps

Cost

High development costs
Accessibility
Insurance coverage

Manufacturing

Scalable production
Quality control
Supply chain

Investment Considerations

Risk Factors

Technical Risk: Long-term implant reliability unproven
Regulatory Risk: Novel technology, evolving FDA guidance
Competition: Multiple well-funded players
Adoption Risk: Patient and physician acceptance

Opportunity Factors

Unmet Need: Millions of paralyzed patients
Technology Maturation: Decade of R&D culminating in human trials
Market Expansion: From rare diseases to broader applications
AI Synergy: Machine learning improving decoding

Market Projections

Addressable Population: ~5 million severe paralysis patients in US
Total Market Size: $5-10B by 2035
Key Milestones: First FDA approvals (2026-2028)
Investment Returns: 5-10x potential for early investors

Cross-References

[Brain-Computer Interface Technologies](/technologies)](/technologies)
[Neuralink - Neuralink technology](/companies/neuralink)](/companies/neuralink)
[OpenBCI - Open source BCI](/technologies/openbci)](/technologies)
[ECoG Brain-Computer Interfaces - Invasive ECoG](/technologies/ecog-bci)](/technologies)
[fNIRS BCI - Functional near-infrared spectroscopy](/technologies/brain-computer-interface)](/technologies)
[Motor Imagery BCI - Motor intention systems](/technologies/brain-computer-interface)](/technologies)
[ALS Communication BCI](/diseases/amyotrophic-lateral-sclerosis)

External Resources

[Neuralink](https://neuralink.com/)](/companies/neuralink)
[Synchron](https://synchron.com/)](/companies/synchron)
[Blackrock Neurotech](https://blackrockneurotech.com/)](/companies/blackrock-neurotech)
[OpenBCI](https://openbci.com/)](/technologies/openbci)
[ClinicalTrials.gov - BCI](https://clinicaltrials.gov/search?cond=Neurodegenerative+Disease&intr=Brain-Computer+Interface)

External Links

[Brain-Computer Interface Research](https://www.nature.com/articles/s41583-020-0275-5)

References

Unknown, Neuralink first human implantation (2024) (2024)

[Unknown, Synchron Stentrode trial results (2024) (2024)](https://doi.org/10.1016/j.neuroimage.2024.120123)

[Unknown, BCI technology review (2023) (2023)](https://doi.org/10.1038/s41586-023-04000-8)

[Unknown, Blackrock Neurotech clinical results (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37654892/)

[Unknown, BCI investment landscape analysis (2024) (2024)](https://doi.org/10.1016/j.neuropharm.2024.109432)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[TREM2-Dependent Microglial Senescence Transition](/hypothesis/h-61196ade) — 0.76 · Target: TREM2
[Targeted Butyrate Supplementation for Microglial Phenotype Modulation](/hypothesis/h-3d545f4e) — 0.72 · Target: GPR109A
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Synthetic Biology BBB Endothelial Cell Reprogramming](/hypothesis/h-84808267) — 0.71 · Target: TFR1, LRP1, CAV1, ABCB1
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — 0.70 · Target: TREM2
[Age-Dependent Complement C4b Upregulation Drives Synaptic Vulnerability in Hippocampal CA1 Neurons](/hypothesis/h-2f43b42f) — 0.70 · Target: C4B
[Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming](/hypothesis/h-f3fb3b91) — 0.67 · Target: TLR4

Related Analyses:

[Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-20260402) 🔄
[Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v2-20260402) 🔄
[Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v3-20260402) 🔄
[Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v4-20260402) 🔄
[Gene expression changes in aging mouse brain predicting neurodegenerative vulnerability](/analysis/SDA-2026-04-02-gap-aging-mouse-brain-v5-20260402) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Brain-Computer Interface Investment Landscape discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

investment-brain-computer-interface

▸Metadataorigin_type: v1_polymorphic_backfill

slug	investment-brain-computer-interface
kg_node_id	None
entity_type	investment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-04ef05186655
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'investment-brain-computer-interface'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

Incoming

484

Outgoing

579

0 supporting 0 contradicting 0 neutral

View full evidence profile →

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

This artifact has no version history yet.

Linked Artifacts (761)

mentions🧪Lipid Droplet Dynamics as Phenotype Switches70%

mentions🧪Purinergic Signaling Polarization Control70%

mentions🧪Mechanosensitive Ion Channel Reprogramming70%

see_also📖HCN1 Gene60%

see_also📖Ferritin Heavy Chain (FTH1)60%

see_also📖CYP46A1 — Cholesterol 24-Hydroxylase60%

see_also📖CNR1 Gene60%

see_also📖GABRD — GABA-A Receptor Delta Subunit60%

see_also📖Amyotrophic Lateral Sclerosis60%

see_also📖AMPK (AMP-Activated Protein Kinase)60%

mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy50%

mentions🧪Sleep Spindle-Synaptic Plasticity Enhancement50%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%

mentions🧪Ephrin-B2/EphB4 Axis Manipulation50%

mentions🧪Synthetic Biology Rewiring via Orthogonal Receptors50%

mentions🧪Fractalkine Axis Amplification via CX3CR1 Positive Allosteri50%

mentions🧪FOXO3-Longevity Pathway Epigenetic Reprogramming50%

mentions🧪Microbiome-Derived Tryptophan Metabolite Neuroprotection50%

mentions🧪TREM2-Dependent Microglial Senescence Transition50%

mentions🧪Partial Neuronal Reprogramming via Modified Yamanaka Cocktai50%

mentions🧪Quantum Coherence Disruption in Cellular Communication50%

mentions🧪TREM2-mediated microglial tau clearance enhancement50%

mentions🧪Microglial Efferocytosis Enhancement via GPR32 Superagonists50%

mentions🧪Smartphone-Detected Motor Variability Correction50%

mentions🧪Correcting Gut Microbial Dopamine Imbalance to Support Syste50%

mentions🧪CX43 hemichannel engineering enables size-selective mitochon50%

mentions🧪Vagal Afferent Microbial Signal Modulation50%

mentions🧪Microglia-Derived Extracellular Vesicle Engineering for Targ50%

mentions🧪Oligodendrocyte White Matter Vulnerability50%

mentions🧪Transcriptional Autophagy-Lysosome Coupling50%

mentions🧪Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Tar50%

mentions🧪Serine/Arginine-Rich Protein Kinase Modulation50%

mentions🧪GAP43-mediated tunneling nanotube stabilization enhances neu50%

mentions🧪Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration50%

mentions🧪Context-Dependent CRISPR Activation in Specific Neuronal Sub50%

mentions🧪Gamma entrainment therapy to restore hippocampal-cortical sy50%

mentions🧪Ganglioside Rebalancing Therapy50%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%

mentions🧪Circadian-Gated Maresin Biosynthesis Amplification50%

mentions🧪R-Loop Resolution Enhancement Therapy50%

mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD50%

mentions🧪Cross-Seeding Prevention Strategy50%

mentions🧪Selective HDAC3 Inhibition with Cognitive Enhancement50%

mentions🧪Epigenetic Memory Erasure via TET2 Activation50%

mentions🧪Mitochondrial Calcium Buffering Enhancement via MCU Modulati50%

mentions🧪Microbial Metabolite-Mediated α-Synuclein Disaggregation50%

mentions🧪Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci50%

mentions🧪Cholesterol-CRISPR Convergence Therapy for Neurodegeneration50%

mentions🧪Sphingomyelin Synthase Activators for Raft Remodeling50%

mentions🧪Hypocretin-Neurogenesis Coupling Therapy50%

mentions🧪Phase-Separated Organelle Targeting50%

mentions🧪Mitochondrial Transfer Pathway Enhancement50%

mentions🧪Autophagosome Maturation Checkpoint Control50%

mentions🧪Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics50%

mentions🧪APOE-TREM2 Interaction Modulation50%

mentions🧪Mitochondrial RNA Granule Rescue Pathway50%

mentions🧪RNA-Binding Competition Therapy for TDP-43 Cross-Seeding50%

mentions🧪Selective Acid Sphingomyelinase Modulation Therapy50%

mentions🧪HSP90-Tau Disaggregation Complex Enhancement50%

mentions🧪Liquid-Liquid Phase Separation Modifier Therapy50%

mentions🧪Prefrontal sensory gating circuit restoration via PV interne50%

mentions🧪Metabolic Circuit Breaker via Lipid Droplet Modulation50%

mentions🧪Astrocyte-Mediated Neuronal Epigenetic Rescue50%

mentions🧪CYP46A1 Overexpression Gene Therapy50%

mentions🧪Nucleolar Stress Response Normalization50%

mentions🧪Transglutaminase-2 Cross-Linking Inhibition Strategy50%

mentions🧪Complement-Mediated Synaptic Pruning Dysregulation50%

mentions🧪Multi-Modal Stress Response Harmonization50%

mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides50%

mentions🧫Traumatic Brain Injury and Alzheimer's Disease Relation50%

mentions🧪Glycosaminoglycan Template Disruption Approach50%

mentions🧪Mitochondrial SPM Synthesis Platform Engineering50%

mentions🧪Axonal RNA Transport Reconstitution50%

mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination50%

mentions🧪Low Complexity Domain Cross-Linking Inhibition50%

mentions🧪Circadian Rhythm Entrainment of Reactive Astrocytes50%

mentions🧪Astroglial Gap Junction Coordination via Connexin-43 Phospho50%

mentions🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation50%

mentions🧪Mitochondrial-Lysosomal Contact Site Engineering50%

mentions🧪AMPK hypersensitivity in astrocytes creates enhanced mitocho50%

mentions🧪LRP1-Dependent Tau Uptake Disruption50%

mentions🧪Flotillin-1 Stabilization Compounds50%

mentions🧪Sphingolipid Metabolism Reprogramming50%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%

mentions🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK50%

mentions🧪Nutrient-Sensing Epigenetic Circuit Reactivation50%

mentions🧪The Glial Ketone Metabolic Shunt Hypothesis50%

mentions🧪Restoring Neuroprotective Tryptophan Metabolism via Targeted50%

mentions🧫Brain Connectivity-Targeted tACS Trial in Early AD50%

mentions🧫s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice 50%

mentions🧪Perforant Path Presynaptic Terminal Protection Strategy50%

mentions🧪Netrin-1 Gradient Restoration50%

mentions🧪Glymphatic System-Enhanced Antibody Clearance Reversal50%

mentions🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech50%

mentions🧪Senescent Microglia Resolution via Maresins-Senolytics Combi50%

mentions🧪APOE-Dependent Autophagy Restoration50%

mentions🧪Extracellular Matrix Stiffness Modulation50%

mentions🧪TFEB-PGC1α Mitochondrial-Lysosomal Decoupling50%

mentions🧪Lysosomal Positioning Dynamics Modulation50%

mentions🧫Microglial TREM2 Agonist In Vivo Efficacy50%

mentions🧪Lysosomal Calcium Channel Modulation Therapy50%

mentions🧪The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction50%

mentions🧪Circadian Clock-Autophagy Synchronization50%

mentions🧪Competitive APOE4 Domain Stabilization Peptides50%

mentions🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro50%

mentions🧪Circadian Glymphatic Entrainment via Targeted Orexin Recepto50%

mentions🧪Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu50%

mentions🧪Retinal Vascular Microcirculation Rescue50%

mentions🧪Circadian-Synchronized Proteostasis Enhancement50%

mentions🧪Enteric Nervous System Prion-Like Propagation Blockade50%

mentions🧪Circadian-Synchronized LRP1 Pathway Activation50%

mentions🧪Digital Twin-Guided Metabolic Reprogramming50%

mentions🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim50%

mentions🧫s:** - Single-cell RNA-seq to measure editing efficiency acr50%

mentions🧪Noradrenergic-Tau Propagation Blockade50%

mentions🧪Arginine Methylation Enhancement Therapy50%

mentions🧪HDAC3-Selective Inhibition for Clock Reset50%

mentions🧪Glial Glycocalyx Remodeling Therapy50%

mentions🧪RNA Granule Nucleation Site Modulation50%

mentions🧪Blood-Brain Barrier SPM Shuttle System50%

mentions🧪Stress Granule Phase Separation Modulators50%

mentions🧪Senescence-Induced Lipid Peroxidation Spreading50%

mentions🧫Gut-Brain Axis Pathogenesis in Parkinson's Disease — Me50%

mentions🧪Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu50%

mentions🧪TFAM overexpression creates mitochondrial donor-recipient gr50%

mentions🧪HCN1-Mediated Resonance Frequency Stabilization Therapy50%

mentions🧪Gut Barrier Permeability-α-Synuclein Axis Modulation50%

mentions🧪Orexin-Microglia Modulation Therapy50%

mentions🧪Bacterial Enzyme-Mediated Dopamine Precursor Synthesis50%

mentions🧪DNMT1-Targeting Antisense Oligonucleotide Reset50%

mentions🧪Chromatin Accessibility Restoration via BRD4 Modulation50%

mentions🧪Magnetosonic-Triggered Transferrin Receptor Clustering50%

mentions🧪Piezoelectric Nanochannel BBB Disruption50%

mentions🧪SASP-Mediated Cholinergic Synapse Disruption50%

mentions🧪APOE-Mediated Synaptic Lipid Raft Stabilization50%

mentions🧪Gap Junction Hemichannel Modulation for Controlled Mitochond50%

mentions🧪Microbial Inflammasome Priming Prevention50%

mentions🧪Optogenetic Microglial Deactivation via Engineered Inhibitor50%

mentions🧪Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy50%

mentions🧪Reelin-Mediated Cytoskeletal Stabilization Protocol50%

mentions🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th50%

mentions🧪Glycine-Rich Domain Competitive Inhibition50%

mentions🧪Senescence-Associated Myelin Lipid Remodeling50%

mentions🧫Brainstem Circuit Modulation for PSP50%

mentions🧪Pericyte Contractility Reset via Selective PDGFR-β Agonism50%

mentions🧪Astrocytic Connexin-43 Upregulation Enhances Neuroprotective50%

mentions🧪Tau-Independent Microtubule Stabilization via MAP6 Enhanceme50%

mentions🧪Biorhythmic Interference via Controlled Sleep Oscillations50%

mentions🧪PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor50%

mentions🧪Senescent Cell Mitochondrial DNA Release50%

mentions🧪Epigenetic Memory Reprogramming for Alzheimer's Disease50%

mentions🧪Adenosine-Astrocyte Metabolic Reset50%

mentions🧪Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioener50%

mentions🧪Lysosomal Enzyme Trafficking Correction50%

mentions🧪Temporal TET2-Mediated Hydroxymethylation Cycling50%

mentions🧪Ocular Immune Privilege Extension50%

mentions🧪Extracellular Vesicle Biogenesis Modulation50%

mentions🧪Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution50%

mentions🧪Chaperone-Mediated APOE4 Refolding Enhancement50%

mentions🧪RAB27A-dependent extracellular vesicle engineering for mitoc50%

mentions🧪VCP-Mediated Autophagy Enhancement50%

mentions🧫Blood-Brain Barrier Aging and Neurodegeneration — From Leaka50%

mentions🧪Lysosomal Membrane Repair Enhancement50%

mentions🧪Synaptic Vesicle Tau Capture Inhibition50%

mentions🧪GFAP-Positive Reactive Astrocyte Subtype Delineation50%

mentions🧪Vocal Cord Neuroplasticity Stimulation50%

mentions🧪Age-Dependent Complement C4b Upregulation Drives Synaptic Vu50%

mentions🧪Trans-Synaptic Adhesion Molecule Modulation50%

mentions🧪SIRT6-NAD+ Axis Enhancement Therapy50%

mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia50%

mentions🧪Microglial Purinergic Reprogramming50%

mentions🧪Complement C1QA Spatial Gradient in Cortical Layers50%

mentions🧪Pharmacological Enhancement of APOE4 Glycosylation50%

mentions🧪Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulat50%

mentions🧪Near-infrared light therapy stimulates COX4-dependent mitoch50%

mentions🧪APOE Isoform Expression Across Glial Subtypes50%

mentions🧪Brain Insulin Resistance with Glucose Transporter Dysfunctio50%

mentions🧪Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption50%

mentions🧪Programmable Neuronal Circuit Repair via Epigenetic CRISPR50%

mentions🧪Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem50%

mentions🧪Metabolic Switch Targeting for A1→A2 Repolarization50%

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna50%

mentions🧪Osmotic Gradient Restoration via Selective AQP1 Enhancement 50%

mentions🧪Circadian Glymphatic Rescue Therapy (Melatonin-focused)50%

mentions🧪KDM6A-Mediated H3K27me3 Rejuvenation50%

mentions🧪Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain A50%

mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%

mentions🧪TET2-Mediated Demethylation Rejuvenation Therapy50%

mentions🧪Palmitoylation-Targeted BACE1 Trafficking Disruptors50%

mentions🧪Metabolic Reprogramming via Microglial Glycolysis Inhibition50%

mentions🧪Purinergic P2Y12 Inverse Agonist Therapy50%

mentions🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr50%

mentions🧪APOE Isoform Conversion Therapy50%

mentions🧪Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m50%

mentions🧪Membrane Cholesterol Gradient Modulators50%

mentions🧪Proteostasis Enhancement via APOE Chaperone Targeting50%

mentions🧪SASP-Driven Aquaporin-4 Dysregulation50%

mentions🧪HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor50%

mentions🧪Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cro50%

mentions🧪Aquaporin-4 Polarization Rescue50%

mentions🧪Optogenetic Control of Mitochondrial Transfer Networks50%

mentions🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli50%

mentions🧪Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro50%

mentions🧪Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflam50%

mentions🧪Synthetic Biology Approach: Designer Mitochondrial Export Sy50%

mentions🧪PARP1 Inhibition Therapy50%

mentions🧪Multi-Modal CRISPR Platform for Simultaneous Editing and Mon50%

mentions🧪Heat Shock Protein 70 Disaggregase Amplification50%

mentions🧪Complement C1q Subtype Switching50%

mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia50%

mentions🧪Cryptic Exon Silencing Restoration50%

mentions🧪Synthetic Biology BBB Endothelial Cell Reprogramming50%

mentions🧪Complement C1q Mimetic Decoy Therapy50%

mentions🧪TREM2-Mediated Selective Aggregate Clearance Pathway50%

mentions🧪SASP-Mediated Complement Cascade Amplification50%

mentions🧪Matrix Stiffness Normalization via Targeted Lysyl Oxidase In50%

mentions🧪Senescence-Activated NAD+ Depletion Rescue50%

mentions🧪Targeted Butyrate Supplementation for Microglial Phenotype M50%

mentions🧪Temporal Decoupling via Circadian Clock Reset50%

see_also📖Manganese-Related Neurodegeneration (Manganism)45%

see_also📖Lipid Metabolism Dysregulation in Neurodegeneration45%

see_also📖Autosis Pathway in Neurodegeneration45%

see_also📖R-Loop Stress in Neurodegeneration45%

see_also📖Alpha-Synuclein Seeding Assays (RT-QuIC and PMCA)45%

see_also📖alexander-disease45%

see_also📖Glycosylation in Neurodegeneration45%

see_also📖Clinical Phenotypes and Subtypes of Corticobasal Syndrome45%

see_also📖Advanced In Vitro Models for Neurodegeneration — Organoids, 45%

see_also📖Multi-Analyte Biomarker Panel for Parkinson's Disease D45%

see_also📖Nutritional Support and Dietary Interventions in Corticobasa45%

see_also📖RNA-Targeted Therapies in Neurodegeneration45%

see_also📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)45%

see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration45%

see_also📖Ubiquitin-Proteasome System Dysfunction in Neurodegeneration45%

see_also📖Synthetic Lethality and PARP Inhibition in Neurodegeneration45%

see_also📖A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-C45%

see_also📖Natural History and Prognosis of Corticobasal Syndrome45%

see_also📖Down Syndrome Neurodegeneration Pathway45%

see_also📖FA2H-Associated Neurodegeneration Pathway45%

see_also📖Tertiary Lymphoid Organs in Neurodegeneration45%

see_also📖Japan Neurodegeneration Epidemiology45%

see_also📖CBS/PSP Panxoneopathy and Membrane Biology45%

see_also📖A Multicenter, Phase III, Randomized, Double Blind, Placebo-45%

see_also📖PSP Liquid-Liquid Phase Separation and Biomolecular Condensa45%

see_also📖Transdiagnostic Proteomic Changes in Neurodegeneration45%

see_also📖CSF and Blood Biomarkers in Progressive Supranuclear Palsy45%

see_also📖A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial45%

see_also📖Histone Modification Pathways in Neurodegeneration45%

see_also📖MicroRNA Dysfunction in Neurodegeneration45%

see_also📖Liquid Biopsy in Neurodegeneration45%

see_also📖Quantum Biology and Coherent Energy Transfer in Neurodegener45%

see_also📖BLAAC PD - Black and African Americans Connections to PD (NC45%

see_also📖Farnesoid X Receptor (FXR) Signaling in Neurodegeneration45%

see_also📖Caregiver Support and Palliative Care in Atypical [Parkinson45%

see_also📖Speech and Language Deficits in Corticobasal Syndrome45%

see_also📖Amylin Signaling in Neurodegeneration45%

see_also📖Shared Mechanisms Between Alzheimer and Parkinson Disease45%

see_also📖C9orf72 Repeat Expansions in CBS and PSP45%

see_also📖Global Neurodegeneration Epidemiology45%

see_also📖Endosomal Sorting Defects in Neurodegeneration45%

see_also📖COVID-19 Neurodegeneration Mechanism45%

see_also📖Geniposide for Alzheimer's disease - immune biomarker t45%

see_also📖Serotonergic Dysfunction in Neurodegeneration45%

see_also📖Protein Aggregation Seeds in Neurodegeneration45%

see_also📖Microglial Priming Pathway in Neurodegeneration45%

see_also📖NLRP3 Inhibitors in Parkinson's Disease: Research and C45%

see_also📖T-Cell Dysfunction in Neurodegeneration45%

see_also📖Antisense Oligonucleotide (ASO) Therapy in Neurodegeneration45%

see_also📖Familial vs Sporadic Neurodegeneration Comparison45%

see_also📖Cognitive and Speech Rehabilitation in CBS (NCT05823421)45%

see_also📖Endosomal-Lysosomal Pathway in Neurodegeneration45%

see_also📖Sigma-1 Receptor Signaling in Neurodegeneration45%

see_also📖Neural Circuits in Neurodegeneration45%

see_also📖becn1-autophagy-initiation-neurodegeneration-causal-chain45%

see_also📖Sex Differences in Neurodegeneration45%

see_also📖PSP and Idiopathic Normal Pressure Hydrocephalus: Clinical O45%

see_also📖Prion Diseases in Neurodegeneration45%

see_also📖ALS Biomarkers and Disease Monitoring45%

see_also📖Computational Disease Models for Neurodegeneration45%

see_also📖Chrononutrition and Time-Restricted Eating in Neurodegenerat45%

see_also📖Gait and Balance Disorders in Progressive Supranuclear Palsy45%

see_also📖SUMOylation in Neurodegeneration45%

see_also📖Social Behaviors and Quality of Life in Parkinson's Dis45%

see_also📖Mirror Therapy and Sensory Re-education in Corticobasal Synd45%

see_also📖Mineralocorticoid Receptor Signaling in Neurodegeneration45%

see_also📖VEGF Signaling and Cerebral Angiogenesis in Neurodegeneratio45%

see_also📖Sirtuin-Mitochondrial Biogenesis Axis in Neurodegeneration45%

see_also📖Mitochondrial Fusion in Neurodegeneration45%

see_also📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St45%

see_also📖Extracellular Vesicle and Tunneling Nanotube-Mediated Spread45%

see_also📖Gait and Upper Limb Evaluation in PSP (NCT07136844)45%

see_also📖Braak Staging and Tau Propagation Pathway45%

see_also📖A 6-month & 18-month Prospective, Randomized, Placebo-co45%

see_also📖Ribosome Dysfunction in Neurodegeneration45%

see_also📖WNK1-Bilirubin Signaling in Neuroinflammation and Neurodegen45%

see_also📖Pseudobulbar Affect and Emotional Lability in Corticobasal S45%

see_also📖Blood-Brain Barrier and Neuroimmune Interface in CBS/PSP45%

see_also📖Magnetic Resonance Spectroscopy in Neurodegeneration45%

see_also📖Galectin-3 Mechanism in Neurodegeneration45%

see_also📖Synaptic Loss and Dysfunction Pathway45%

see_also📖Nitric Oxide Signaling in Neurodegeneration45%

see_also📖Neuropil Threads in Neurodegeneration45%

see_also📖Integrated Stress Response in Neurodegeneration45%

see_also📖India Neurodegeneration Epidemiology45%

see_also📖Neurovascular Unit Dysfunction in Neurodegeneration45%

see_also📖Neuroimaging Biomarkers for Neurodegeneration45%

see_also📖PKR Pathway in Neurodegeneration45%

see_also📖Nuclear Pore Complex Dysfunction in Neurodegeneration45%

see_also📖Beta-Propeller Protein-Associated Neurodegeneration (BPAN)45%

see_also📖Vocational Rehabilitation and Driving in Corticobasal Syndro45%

see_also📖Pantothenate Kinase-Associated Neurodegeneration (PKAN)45%

see_also📖PSP Tau Propagation and Spreading Mechanisms45%

see_also📖NRF2 Signaling Pathway in Neurodegeneration45%

see_also📖CARASIL (Cerebral Autosomal Recessive Arteriopathy with Subc45%

see_also📖Disease Progression & Staging in Neurodegeneration45%

see_also📖Blood-Brain Barrier Dysfunction and Therapeutic Delivery for45%

see_also📖FTLD-TDP Subtypes and Mechanisms45%

see_also📖APOE4 and Alzheimer's Disease Risk45%

see_also📖Neuroinflammation in Parkinson's Disease Dementia and D45%

see_also📖Advanced Glycation End Products in Neurodegeneration45%

see_also📖PPAR Signaling Pathway in Neurodegeneration45%

see_also📖ESCRT-III Inhibition by Alpha-Synuclein in Neurodegeneration45%

see_also📖Neurofilament Light Chain (NfL) Mechanism in Neurodegenerati45%

see_also📖Protein Aggregation Comparison in Neurodegeneration45%

see_also📖Economic Burden — Neurodegeneration45%

see_also📖Investment Landscape: Parkinson's Disease45%

see_also📖IGF-1 Signaling Pathway in Neurodegeneration45%

see_also📖PI-2620 Tau PET Phase 3 (NCT05456503) - FTLD and Atypical AD45%

see_also📖Myoclonus and Cortical Hyperexcitability in Corticobasal Syn45%

see_also📖Cortical Involvement and Neurodegeneration in Progressive Su45%

see_also📖Caregiver Burden and Support in Corticobasal Syndrome45%

see_also📖Digital Therapeutic Platform for Swallowing and Drooling Pro45%

see_also📖NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease45%

see_also📖Pupillometry and Chromatic Pupillometry in Corticobasal Synd45%

see_also📖Investment Landscape: Frontotemporal Dementia45%

see_also📖Clinical Efficacy and Mechanism of tDCS for Dysphagia in Par45%

see_also📖Prion-Like Spread in Neurodegeneration45%

see_also📖Sleep and Circadian Dysfunction in Alzheimer's Disease45%

see_also📖Olfactory Mucosa, Blood and Urine for Identification of Earl45%

see_also📖IL-1 Signaling Pathway in Neurodegeneration45%

see_also📖Mitochondrial Dynamics Pathway in Neurodegeneration45%

see_also📖Prion Protein Metabolism in Neurodegeneration45%

see_also📖Kidney-Brain Neurodegeneration Axis45%

see_also📖Polygenic Risk Score Integration Panel for Alzheimer's 45%

see_also📖Cerebral Amyloid Angiopathy Pathway in Neurodegeneration45%

see_also📖Utilisation of Health Services and Quality of Life in Atypic45%

see_also📖Copper Homeostasis in Neurodegeneration45%

see_also📖Dysphagia and Nutritional Management in Corticobasal Syndrom45%

see_also📖GDF15/GDF11 Signaling in Neurodegeneration45%

see_also📖VEGF and Angiogenesis Dysregulation in CBS/PSP45%

see_also📖vip-vasoactive-intestinal-peptide-signaling-neurodegeneratio45%

see_also📖Glial Tau Pathology in PSP and CBD45%

see_also📖Exosomal Biomarkers in Neurodegeneration45%

see_also📖Sleep Disorders in Neurodegeneration45%

see_also📖Gangliosides in Neurodegeneration45%

see_also📖Retinal Degeneration Pathway in Neurodegeneration45%

see_also📖Neuronal Hyperexcitability in Neurodegeneration45%

see_also📖PSP Lysosomal Dysfunction and Autophagy Impairment45%

see_also📖Axon Guidance Pathways in Neurodegeneration45%

see_also📖Endothelin Signaling Pathway in Neurodegeneration45%

see_also📖Neuropeptide Y Signaling in Neurodegeneration45%

see_also📖Sandhoff Disease45%

see_also📖Hemiballismus and Hemichorea in Corticobasal Syndrome45%

see_also📖Investment Landscape: Huntington's Disease45%

see_also📖Advanced Proteolysis and Ubiquitin System Targeting in CBS/P45%

see_also📖Homocysteine Neurotoxicity and Neurodegeneration45%

see_also📖Purinergic Signaling in Neurodegeneration45%

see_also📖Cognitive Reserve and Resilience in Neurodegeneration45%

see_also📖MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acid45%

see_also📖Pupillary and Visual Dysfunction in Progressive Supranuclear45%

see_also📖Environmental Toxins and Parkinson's Risk45%

see_also📖Ghrelin Signaling Pathway in Neurodegeneration45%

see_also📖Rotigotine and Rivastigmine Combination Therapy for Alzheime45%

see_also📖Japanese and German Case Series in Corticobasal Degeneration45%

see_also📖Digital Phenotyping in Neurodegeneration45%

see_also📖LRRK2 Gene Variants and Mutations45%

see_also📖Postural Dysfunction and Abnormalities in Corticobasal Syndr45%

see_also📖Antibody Therapy in Neurodegeneration45%

see_also📖Whole-Body Photobiomodulation for Motor and Cognitive Change45%

see_also📖LRRK2 Kinase Activation and Endolysosomal Dysfunction in Par45%

see_also📖ALS Therapeutic Landscape — Programs by Phase and Modality45%

see_also📖epigenetics-neurodegeneration45%

see_also📖Ribonuclease κ and Circular RNAs: A New Mechanism of Aging a45%

see_also📖Mitochondrial Diseases and Neurodegeneration Comparison Matr45%

see_also📖Cross-National Cancer-Dementia Correlation and Shared Diseas45%

see_also📖OSK Reprogramming and Yamanaka Factors in Neurodegeneration45%

see_also📖Clostridium Butyricum for Motor and Non-motor Symptoms in Pa45%

see_also📖Prognostic Biomarkers in Neurodegeneration45%

see_also📖Voice and Speech in Corticobasal Syndrome45%

see_also📖Therapeutic Targets in Neurodegeneration45%

see_also📖Iron and Neuromelanin Accumulation in PSP45%

see_also📖A Phase IIB, Randomized, Double-Blind, Placebo-Controlled, M45%

see_also📖Cell-Free DNA Biomarkers in Neurodegeneration45%

see_also📖Quality of Life and Caregiver Burden in PSP (NCT03638505)45%

see_also📖Intrinsic Apoptosis Pathway in Neurodegeneration45%

see_also📖Tau Seeding and Propagation Pathway45%

see_also📖AAIC 2026: Tau-PET Imaging and Fluid Biomarker Integration45%

see_also📖Sleep Architecture Changes in CBS and PSP45%

see_also📖PLA2G6-Associated Neurodegeneration (PLAN)45%

see_also📖Neurexin/Neuroligin Synaptic Adhesion Modulator Therapy in N45%

see_also📖mTOR Signaling in Autophagy and Lysosomal Function45%

see_also📖Endocannabinoid System in Neurodegeneration45%

see_also📖Alpha-Synuclein PET Imaging and Biomarker Advances45%

see_also📖p-Tau Biomarker in Immunoglobulin Light Chain and Transthyre45%

see_also📖Cancer-Dementia Inverse Correlation: Epidemiological Evidenc45%

see_also📖PSP Weight Loss and Cachexia45%

see_also📖P-Body (Processing Body) Pathway in Neurodegeneration45%

see_also📖Orexin Signaling in Neurodegeneration45%

see_also📖Neural Circuit Disruption in Neurodegeneration45%

see_also📖HMGB1 Signaling in Neurodegeneration45%

see_also📖Parthanatos in Neurodegeneration45%

see_also📖Sialorrhea and Drooling in Corticobasal Syndrome45%

see_also📖Speech and Voice Disorders in PSP45%

see_also📖Glymphatic and Vascular Clearance Dysfunction in 4R-Tauopath45%

see_also📖Senescent Cell Clearance in Neurodegeneration45%

see_also📖HLA Haplotypes and Neuroinflammatory Profiles in PSP45%

see_also📖US Neurodegeneration Epidemiology45%

see_also📖Neurodegeneration with Brain Iron Accumulation (NBIA)45%

see_also📖Metabolic Dysfunction and Insulin Resistance in Progressive 45%

see_also📖Multimodal Diagnostic Algorithm for CBS and PSP45%

see_also📖Diffusion MRI (DTI) in Neurodegeneration45%

see_also📖CNversyt and Megan Rodden ALS Trials45%

see_also📖Systemic Infection and Tau Pathology Acceleration45%

see_also📖Metal Homeostasis Dysregulation in Neurodegeneration45%

see_also📖BEACoN Study - Biomarker Exploration in Aging, Cognition and45%

see_also📖Glucocorticoid Signaling Pathway in Neurodegeneration45%

see_also📖Long-term Effects of Hearing Intervention on Brain Health in45%

see_also📖Synaptic Therapy Alzheimer's Research Trial (START): A 45%

see_also📖Pericyte Loss in Neurodegeneration45%

see_also📖interleukin-6-signaling-neurodegeneration45%

see_also📖Hippocampal Neurogenesis in Neurodegeneration45%

see_also📖Dystrophic Neurites in Neurodegeneration45%

see_also📖China Neurodegeneration Epidemiology45%

see_also📖Neurotensin Signaling in Neurodegeneration45%

see_also📖Short Chain Fatty Acids in Neurodegeneration45%

see_also📖Investment Landscape: ALS45%

see_also📖Synaptic Biomarkers in Neurodegeneration45%

see_also📖gp130/IL-6 Family Cytokine Signaling in Neurodegeneration45%

see_also📖GDNF Signaling Pathway in Neurodegeneration45%

see_also📖Healthcare Economics and Cost of Illness in Progressive Supr45%

see_also📖mTOR Signaling Pathway in Neurodegeneration45%

see_also📖Peripheral Immune-Brain Crosstalk in Neurodegeneration45%

see_also📖Neuroresilience Mechanisms and Evidence45%

see_also📖ABCA7 Lipid Transport and Microglial Phagocytosis AD Causal 45%

see_also📖Potential Impact Measures — Neurodegeneration45%

see_also📖Callosal Disconnection and Interhemispheric Dysfunction in C45%

see_also📖Lysosomal Calcium Dysregulation in Neurodegeneration45%

see_also📖Swedish BioFINDER 2 Study: Biomarkers and Neurodegeneration 45%

see_also📖Imaging Biomarkers for Corticobasal Syndrome and Progressive45%

see_also📖Simultanagnosia and Balint's Syndrome in Corticobasal S45%

see_also📖Sleep Dysfunction in Neurodegeneration45%

see_also📖Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pi45%

see_also📖First-in-Human 4R Tau Ligand Study in PSP (NCT07348276)45%

see_also📖Noradrenergic Signaling Pathway in Neurodegeneration45%

see_also📖HIV-Associated Neurocognitive Disorders (HAND)45%

see_also📖FTDP-17 Clinical Phenotypes and Disease Progression45%

see_also📖Silymarin for Neuroprotection and Symptom Management in Park45%

see_also📖acetylcholine-signaling-neurodegeneration45%

see_also📖Jervell and Lange-Nielsen Syndrome45%

see_also📖IL-6 (Interleukin-6) in Neurodegeneration45%

see_also📖Metal Homeostasis in Neurodegeneration45%

see_also📖VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers45%

see_also📖Lipid Dysregulation in Neurodegeneration45%

see_also📖Alexander Disease Genetic Variants45%

see_also📖Molecular Chaperones in Neurodegeneration45%

see_also📖ATP13A9 and Parkinson's Disease45%

see_also📖Progesterone Signaling Pathway in Neurodegeneration45%

see_also📖Safety and Clinical Outcomes Study: Amniotic and Umbilical C45%

see_also📖synaptic-vesicle-cycling-neurodegeneration45%

see_also📖Speech Therapy and Communication Aids in Corticobasal Syndro45%

see_also📖DALY Methodology — Neurodegeneration45%

see_also📖Phase 3 Study to Compare the Efficacy and Safety of Masitini45%

see_also📖SNCA Gene Variants and Mutations45%

see_also📖GBA Brain Molecular Imaging and Blood Biomarkers for Precisi45%

see_also📖mTOR Signaling in Neurodegeneration45%

see_also📖GBA Glucocerebrosidase Dysfunction and Parkinson's Dise45%

see_also📖Mitochondrial Membrane Protein-Associated Neurodegeneration 45%

see_also📖RAN Translation in Neurodegeneration45%

see_also📖Speech and Cognitive Biomarkers for Alzheimer's Disease45%

see_also📖Vagus Nerve Pathway in Neurodegeneration45%

see_also📖Hereditary Sensory and Autonomic Neuropathy (HSAN)45%

see_also📖MSA Clinical Features and Diagnosis45%

see_also📖Paranodal Dysfunction in Neurodegeneration45%

see_also📖Gait Analysis Parameter and Upper Limb Evaluation in Neurolo45%

see_also📖Pesticides and Parkinson Disease (Pest-PD) — NCT0642031045%

see_also📖PCDH19-Related Epilepsy (EFMR) — Preclinical Gene Therapy Pr45%

see_also📖Physical and Occupational Therapy in Corticobasal Syndrome45%

see_also📖Metabolomic Biomarkers in Neurodegeneration45%

see_also📖Somatic Mutations and Brain Mosaicism45%

see_also📖Cholinergic System Dysfunction in Neurodegeneration45%

see_also📖CaMKII Signaling Pathway in Neurodegeneration45%

see_also📖Cerebral Amyloid Angiopathy in Neurodegeneration45%

see_also📖Carbonic Anhydrase Modulator Therapy in Neurodegeneration45%

see_also📖Exosomal miR-155 in Neurodegeneration45%

see_also📖Glymphatic Clearance Hypothesis — Impaired Aβ and Tau Remova45%

see_also📖Wnt/β-Catenin Signaling Pathway in Neurodegeneration45%

see_also📖A Phase III, Randomized, Double-Blind, Placebo-Controlled, M45%

see_also📖ubiquitin-proteasome-dysfunction-neurodegeneration45%

see_also📖Convergent Pathways in Neurodegeneration45%

see_also📖RNA Splicing in Neurodegeneration45%

see_also📖Quality of Life and Caregiver Burden in Progressive Supranuc45%

see_also📖Ion Channel Dysfunction in Neurodegeneration: Cross-Disease 45%

see_also📖NF-kB Signaling Pathway in Neurodegeneration45%

see_also📖S100 Protein Signaling Pathway in Neurodegeneration45%

see_also📖Protein O-GlcNAcylation Pathway in Neurodegeneration45%

see_also📖Basal Ganglia Circuit Dysfunction in Neurodegeneration45%

see_also📖A Phase 3, Randomized, Double-blind, Placebo-controlled, Par45%

see_also📖mitochondrial-dysfunction-neurodegeneration-comparison45%

see_also📖European Neurodegeneration Epidemiology45%

see_also📖Paraptosis in Neurodegeneration45%

see_also📖TBK1 Autophagy and Neuroinflammation ALS/FTD Causal Chain45%

mentions🧫TLR expression analysis in Parkinson's disease patients44%

mentions🧫TLR expression in α-synuclein overexpressing mice44%

mentions🧫TLR4 Activation Assay with NETs and Anti-CarP Antibodies44%

mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%

mentions🔬Investigate prion-like spreading of tau pathology through co40%

mentions🔬What gene expression changes in the aging mouse brain predic40%

mentions🔬What are the mechanisms underlying what are the mechanisms b40%

mentions🔬Can gut-brain axis modulation prevent or slow Alzheimer'40%

mentions🔬How does metabolic reprogramming (glucose metabolism shifts,40%

mentions🔬What cell types are most vulnerable in Alzheimers Disease ba40%

mentions🔬Analyze circuit-level changes in neurodegeneration using All40%

mentions🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br40%

related🧪Complement C1q Subtype Switching40%

related🧪PARP1 Inhibition Therapy40%

mentions🔬What are the mechanisms underlying blood-brain barrier trans40%

mentions🔬What are the mechanisms by which tau pathology spreads throu40%

related🧪Ganglioside Rebalancing Therapy40%

related🧪Netrin-1 Gradient Restoration40%

related🧪Aquaporin-4 Polarization Rescue40%

mentions🔬What are the mechanisms underlying mechanistic role of apoe 35%

mentions🔬What are the mechanisms underlying synaptic pruning by micro35%

mentions🔬What are the mechanisms underlying microglia-astrocyte cross35%

mentions🔬What are the mechanisms underlying mitochondrial transfer be35%

mentions🔬What are the mechanisms underlying 4r-tau strain-specific sp35%

mentions🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas35%

mentions🔬What are the mechanisms underlying protein aggregation cross35%

mentions🔬What are the mechanisms underlying apoe4 structural biology 35%

mentions🔬What are the mechanisms underlying selective vulnerability o35%

mentions🔬Epigenetic reprogramming in aging neurons35%

mentions🔬What are the mechanisms underlying neuroinflammation resolut35%

mentions🔬What are the mechanisms underlying perivascular spaces and g35%

mentions🔬What are the mechanisms underlying tdp-43 phase separation t35%

mentions🔬What are the mechanisms underlying senolytic therapy for age35%

mentions🔬What are the mechanisms underlying rna binding protein dysre35%

mentions🔬What are the mechanisms underlying digital biomarkers and ai35%

mentions🔬What are the mechanisms underlying sleep disruption as cause35%

mentions🔬Investigate how lipid raft composition (cholesterol metaboli35%

mentions🔬What are the mechanisms underlying autophagy-lysosome pathwa35%

mentions🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc35%

mentions🔬What are the mechanisms underlying epigenetic clocks and bio35%

mentions🔬What are the mechanisms underlying mitochondrial transfer be35%

mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di35%

mentions🔬What are the mechanisms underlying astrocyte reactivity subt35%

Reference URLs

Canonical (singular)/artifact/wiki-investment-brain-computer-interfacecanonical

Canonical (plural, REST)/artifacts/wiki-investment-brain-computer-interfacealias

API (JSON)/api/artifacts/wiki-investment-brain-computer-interfaceapi

Citation — BibTeX/artifacts/wiki-investment-brain-computer-interface/cite?fmt=bibtexexport

Citation — RIS/artifacts/wiki-investment-brain-computer-interface/cite?fmt=risexport

Citation — CSL-JSON/artifacts/wiki-investment-brain-computer-interface/cite?fmt=cslexport

Embed this artifact

Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.

HTML iframe

<iframe src="http://scidex.ai/artifact/wiki-investment-brain-computer-interface?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[Brain-Computer Interface Investment Landscape](http://scidex.ai/artifact/wiki-investment-brain-computer-interface)

Direct URL

http://scidex.ai/artifact/wiki-investment-brain-computer-interface

Preview

🔄 Adjacent Artifacts Recommended based on your interests

💬 Discussion

Loading comments...

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Brain-Computer Interface Investment Landscape

Executive Summary

Technology Overview

BCI Modalities

Key Technology Categories

Pipeline and Companies

Clinical-Stage BCI Companies

Executive Summary

Technology Overview

BCI Modalities

Key Technology Categories

Pipeline and Companies

Clinical-Stage BCI Companies

Key Players

1. Neuralink (Elon Musk)

2. Synchron

3. Blackrock Neurotech

4. Paradromics

Non-Invasive BCI Companies

Investment Analysis

Funding Trends (2020-2025)

Investment Themes

Clinical Applications in Neurodegeneration

Current Applications

Clinical Trials

Gap Analysis

Technical Gaps

Clinical Gaps

Commercial Gaps

Investment Considerations

Risk Factors

Opportunity Factors

Market Projections

Cross-References

Related Pages

External Resources

See Also

External Links

References

Related Hypotheses

Pathway Diagram

💬 Discussion